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ABSTRACT 
Biopsy-proven acute cellular rejection (ACR) is the primary efficacy endpoint in most 
randomized trials evaluating immunosuppression in liver transplantation. However ACR is 
not a major cause of graft loss, and a certain grade of immune activation may be even 
beneficial for long-term graft acceptance. Validated criteria to select candidates for liver 
biopsy are lacking, and routine clinical practice relies on liver tests, which are inaccurate 
markers of ACR. Indeed, both the agreement among clinicians to select candidates for liver 
biopsy, and the correlation between the clinical suspicion of ACR and histological findings 
are poor. In randomized trials evaluating immunosuppression protocols, this concern grows 
exponentially due to the open-label and multicenter nature of most studies. Therefore biopsy-
proven ACR is a suboptimal efficacy endpoint given its limited impact on prognosis and the 
heterogeneous diagnosis, which may increase the risk of bias. Chronic rejection and/or graft 
loss would be more appropriate endpoints, but would certainly require larger studies with 
prolonged surveillances.  An objective method to select candidates for liver biopsy is 
therefore urgently needed, and only severe episodes of histological ACR should be 
considered as potentially harmful. Emerging surrogate markers of ACR and antibody-
mediated rejection require further investigation to determine their clinical role.  
 
 
Abbreviations: ACR: acute cellular rejection; LT: liver transplantation; RCT: randomized 
controlled trial; CNI: calcineurin inhibitors; AMR: antibody-mediated rejection. 
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INTRODUCTION 
Acute cellular rejection (ACR) is a frequent event early after liver transplantation (LT) which 
occurs in up to 40% of patients, although the rates reach 80% in series with protocol 
biopsies[1]. The majority of ACR episodes occur within the first year after LT. These 
features make ACR a very attractive efficacy endpoint for randomized controlled trials 
(RCTs) evaluating immunosuppression protocols, as fewer patients with shorter surveillance 
are needed for an adequately powered design. The derived reduction of operational costs is 
significant and favors the feasibility of RCTs. However a suitable primary efficacy endpoint 
for RCTs evaluating therapeutic interventions should gather other elements such as a well 
established impact on prognosis and an objective and reproducible assessment. Indeed the 
PRECIS tool (Pragmatic-Explanatory Continuum Indicator Summary), aiming to guide the 
design of clinical trials, describes an adequate primary outcome as “one objectively measured 
and clinically meaningful”, although in some studies with a predominant explanatory 
component the primary efficacy outcome “may be a surrogate marker of a downstream 
outcome of interest”[2]. Existing evidence suggests that none of these criteria is met by 
biopsy-proven ACR in the LT setting. In this systematic review the role of biopsy-proven 
ACR in LT is critically analyzed in order to better understand its impact on the risk of bias in 
RCTs evaluating immunosuppression after LT. In addition, some recommendations are made 
to improve the design of future RCTs.  
 
METHODS 
A search on MEDLINE, Cochrane Controlled Trial Register (CENTRAL), EMBASE and 
Science Citation Index databases was done from January 2007 to September 2015, to analyze 
the current assessment of ACR in RCTs and in observational studies. We identified studies 
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using the following keywords: “liver transplantation”, “rejection”, “immunosuppression” and 
“liver biopsy”. Equivalent free-text terms were used, without language restrictions. 
Additional relevant studies published before 2007, and not reproduced more recently, were 
hand searched. The search resulted in 1449 records which were categorized and screened 
independently by MRP and ET (differences resolved by MM). Duplicate records, reviews, 
studies on pediatric population, and unrelated articles were removed resulting in 97 eligible 
studies including 63 observational studies and 34 RCTs (figure 1). Among these, 2 RCTs 
published as abstracts within the evaluated period were included although they did not 
provide information about the definition of ACR[3,4]. 
 
1) ANALYSIS OF BIOPSY-PROVEN ACR AS AN EFFICACY ENDPOINT FOR 
RCTs. 
1.1) Clinical relevance of ACR in LT 
In the past, the main caveat after solid organ transplantation was the development of 
aggressive treatment-resistant rejection and subsequent graft loss. With the development of 
potent immunosuppressants, particularly calcineurin inhibitors (CNI), and with increasing 
clinical experience, rejection rates decreased significantly and survival was prolonged. 
Nowadays the major causes of death after solid organ transplantation are infections, renal 
insufficiency, cardiovascular events and de novo malignancies, which are not related to the 
transplantation per se, but strongly influenced by the exposure to immunosuppressants[5]. 
The relevance of rejection was diminished, but to a different extent depending on the organ 
considered. In renal transplantation a single episode of ACR or antibody-mediated rejection 
(AMR), even if subclinical, may lead to chronic rejection and graft loss[6]. Likewise, in heart 
and lung transplantation, ACR is able to cause an irreversible damage to the graft[7,8]. The 
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liver, however, is an immunologically privileged organ, probably due to its dual blood-flow 
supply, its huge regeneration potential, its capacity to clear circulating antibodies and the 
constant interaction with a wide spectrum of intestinal antigens. A positive crossmatch does 
not represent a contraindication for LT[9], and it has been suggested, not without 
controversy, that the liver may confer a certain protection against kidney rejection in 
combined organ recipients[10]. Although ACR is frequent after LT, the response to boluses 
of corticosteroids is successful in >80% of patients and the rates of chronic rejection remain 
low under current tacrolimus-based immunosuppression protocols[11]. The risk of chronic 
rejection and graft loss is increased in case of repeated episodes of severe ACR unresponsive 
to steroids and when ACR occurs late (>3 months after LT)[12-15]. Such rather rare 
conditions are usually restricted to a subpopulation of patients with autoimmune liver 
diseases[14,16]. Only 2%-4% of patients will experience graft loss due to chronic rejection 
according to data from European and US registries[5,17].  
In prolonged follow-up series with protocol biopsies early after LT, patients experiencing at 
least one episode of ACR, far from having an impaired prognosis, exhibit an improved long-
term survival[12,18]. Even patients with moderate-severe ACR, responding to boluses of 
steroids, had a benefit in terms of survival when compared with patients without ACR[18]. 
This may be particularly true for patients without hepatitis C who, hopefully, will form the 
vast majority among the LT population in the upcoming years due to the widespread 
availability of the new antivirals. In light of these observations, it has been hypothesized that 
a certain grade of immunological insult could benefit the engraftment, while promoting 
operational tolerance and using minimal immunosuppression in the long-term[19]. Aiming at 
a complete suppression of ACR at all costs, by using increased exposure and number of 
immunosuppressants, is not only unnecessary and inconvenient after LT[20], but would 
adversely affect long-term outcome[21].  
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A recent RCT evaluating a combination of belatacept, basiliximab, mycophenolate and 
steroids was prematurely terminated because of increased rates of graft loss and death 
compared to simpler regimes (tacrolimus+/-mycophenolate), although none of the deaths 
were attributable to ACR[22]. In another double blind trial with protocol liver biopsies, 156 
patients were randomized to tacrolimus monotherapy vs tacrolimus and steroids[23]. 
Although at day 7 moderate-severe histological ACR was present in almost 50% of the study 
population, 5-year incidence of chronic rejection was only 2.4%, while the 5-year patient and 
graft survival rates were excellent (76% and 79% in each arm respectively).  Thus biopsy-
proven ACR after clinical suspicion does not meet the criterion of “clinically meaningful” for 
efficacy endpoints in RCTs[2].  
1.2) Selection of candidates for liver biopsy after LT  
Although ACR graded following Banff criteria is an objective and validated outcome[24] 
within protocol biopsy populations[25], most LT programs have abandoned this strategy, 
claiming increased costs and derived complications. Overall complication rates after liver 
biopsy in adults are 6.7%, but major complications are infrequent (0.5%) and mortality rates 
are <0.1%[26,27]. Several factors related to an increased risk of ACR including (but not 
restricted to) younger age[28-31], vitamin D deficiency[32,33], pre-transplant cardiac 
dysfunction[34] and autoimmune liver disease[16], have not been routinely taken into 
account to guide clinical decisions. Nowadays, only those patients with clinical suspicion of 
rejection, which usually means otherwise unexplained raising transaminases and/or 
cholestatic parameters, are selected for liver biopsy. This strategy, termed as biopsy-proven 
ACR after clinical suspicion, is used as the primary efficacy endpoint in most RCTs 
evaluating immunosuppression in LT. Indeed, from 2007 to 2015, 34 RCTs evaluating 
immunosuppression were published[3,4,22,35-65] (table 1), and among them only 2 studies 
(5.8%) implemented protocol biopsies early after LT to assess ACR[40,43]. The remaining 
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32 RCTs (94.2%) relied on biopsy-proven ACR as efficacy endpoint: in 20 studies biopsy-
proven ACR was the primary efficacy endpoint, either alone (n=14) or as part of a composite 
endpoint (n=6). Biopsy-proven ACR was kept as a secondary efficacy endpoint in the 
remaining 12 studies which aimed to prevent recurrence of hepatitis C (n=4), to preserve 
renal function (n=6), to minimize post-LT diabetes mellitus (n=1) and to analyze 
pharmacokinetics (n=1).  
However liver tests are neither sensitive nor specific for ACR, and there are no defined 
thresholds to determine if a patient is at risk or not for ACR at a certain time point post-
LT[66]. Among 30 RCTs assessing biopsy-proven ACR published in full between 2007 and 
2015 (table 1), 28 studies (93.3%) did not provide any criteria to select candidates for liver 
biopsy, and some of them even accepted a “pure” clinical diagnosis of ACR without 
histological evaluation[39,42,46,47,63]. The latter practice, not supported by clinical 
guidelines, may lead to misdiagnosis and unnecessary anti-rejection therapy, which has been 
linked to inferior graft survival[67]. In such studies without defined criteria, the decision to 
perform liver biopsy was left to the discretion of the responsible clinician according to the 
routine clinical practice from each institution, which may vary among clinicians (even within 
the same center), and may introduce a significant heterogeneity in the diagnosis of ACR. The 
risk of performance and detection bias is increased, but grows exponentially in the two 
following situations: a) Multicenter studies: More participating institutions means more 
clinicians involved in the decision-making process, having different practices regarding 
selecting candidates for liver biopsy. Among the RCTs included in table 1, 63% were 
multicenter (n=20), involving a median of 13 different institutions per study (IQR 8-38); b) 
Open-label design: Nearly all RCTs in table 1 were open-label (29 out of 32; 90.6%). The 
clinician was aware of the immunosuppression protocol and it is possible that he would be 
more worried about ACR in those patients having received less potent immunosuppression 
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protocols. In a certain patient with a mild-moderate modification of liver tests the indication 
for a liver biopsy could rely on the immunosuppression protocol; thus a patient having a 
priori more potent immunosuppression (more drugs and/or higher exposure) may avoid liver 
biopsy if an improvement occurs, whereas a patient under a priori less potent protocol 
(monotherapy with CNI or reduced exposure) would be more likely to undergo a liver biopsy. 
The full impact of these factors is difficult, if not impossible, to assess given that the rates of 
liver biopsy in each comparison arm are not reported in RCTs.  
The agreement among clinicians to select patients with clinical suspicion of rejection was 
explored in a recent study including 100 LT patients with protocol biopsies and histological 
assessment of ACR early after LT[29]. The relevant clinical information between LT and the 
protocol liver biopsy including demographics, etiology of liver disease, immunosuppression 
and daily liver tests, was given to 9 highly-experienced clinicians from 3 transplant centers 
who decided if a liver biopsy was needed on an individual case basis. The concordance 
among clinicians to advice liver biopsy was poor (κ<0.40 in 76% of comparisons), but even 
more striking was the low concordance between the “clinical suspicion of ACR” and the 
presence of actual features of histological ACR in the protocol liver biopsy (κ<0.30 in all 
cases)[29]. These findings reinforce the hypothesis that the evaluation of an objective and 
prospectively validated outcome as it is histological ACR assessed by the Banff criteria, has 
been transformed into a subjective and partially evaluated outcome. Therefore biopsy-proven 
ACR after clinical suspicion does not meet the criterion “objectively measured” for efficacy 
endpoints to be used in RCTs. 
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2) RECOMMENDATIONS TO OPTIMIZE THE ASSESSMENT OF ACR WITHIN 
RCTs. 
2.1) Mild-moderate histological ACR should not be considered an adverse outcome 
In clinical practice the minimization of immunosuppression is gaining adepts[68]. In the last 
decade several RCTs have evaluated protocols with reduced exposure to CNI, either by 
lowering their trough concentrations or by delaying their introduction. Most of these trials 
added new drugs such as mTOR inhibitors[53,56], mycophenolate[46,51], anti-
IL2r[46,48,65] or antithymocyte globulin[47,64] in order to counteract the expected 
increased risk of ACR, and thus many authors are of the opinion that there was not a true 
minimization. There is a demand for RCTs evaluating protocols with complete avoidance (or 
early withdrawal) of CNI or, if these drugs are to be kept, to use them as monotherapy and/or 
with reduced trough concentrations. These strategies may require a protocolized histological 
evaluation, and may be accompanied by increased rates of ACR, but most patients may 
experience a benefit in the long-term.  
In the past, several studies had to stop the CNI free (or early withdrawal) arm due to 
increased biopsy-proven ACR rates. In the H2304 study[53] the role of everolimus as a renal 
sparing agent was explored, either in monotherapy (after tacrolimus withdrawal within 4 
months after LT) or in combination with reduced tacrolimus. The control group received 
tacrolimus and steroids. The everolimus monotherapy arm was stopped due to increased rates 
of biopsy-proven ACR (19.9%) when compared with the reduced tacrolimus and everolimus 
arm (4.1%) and the control group (10.7%), although most ACR episodes were mild, and there 
were no differences in terms of graft loss/death[53]. Most patients in the everolimus 
monotherapy group were then converted to other immunosuppression regimes, but still in the 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
24-months extension study, they exhibited the best glomerular filtration rates[69]. Indeed the 
PROTECT trial, which also evaluated everolimus monotherapy after tacrolimus withdrawal 
(within 12 months after LT), showed similar rates of biopsy-proven ACR in the interventional 
arm (17.7%), but the trial was not stopped and there was a sustained benefit on renal function 
at 3 years[56,70]. Another RCT evaluated antithymocyte globulin as a tacrolimus sparing 
agent[47], a protocol widely used in renal transplantation, even for patients at increased 
immunological risk[71]. Again the trial in LT patients was stopped because increased rates of 
ACR with antithymocyte globulin (52.4%) as compared with controls (25%), although most 
ACR episodes in the interventional arm were mild not requiring boluses of steroids. Not a 
single episode of steroid-resistant ACR occurred.  
Despite all these evidences, histological ACR, if properly assessed, may still provide relevant 
information about graft allo-reactivity. The clue resides in the fact that histological ACR 
needs to be interpreted as a dynamic process which takes place in around 80% of patients at 
some point[40,66,67]. In most of these patients there will only be mild histological changes 
without pathological consequences, even when they are associated with raising 
transaminases. In RCTs, only severe episodes of histological ACR, or moderate episodes not 
responding to boluses of steroids, should be considered as negative events. Mild episodes of 
histological ACR or moderate changes responding well to boluses of steroids should not form 
part of any stopping rule or efficacy endpoint in RCTs, as they do not adversely impact long 
term outcome[12,18,67].  
2.2) The selection of candidates for liver biopsy should be standardized 
In RCTs aiming at aggressive minimization or complete avoidance of CNI, it is absolutely 
necessary to perform protocol liver biopsies with a central and blinded pathology reading, 
particularly early after LT, and this may be ethically fitting considering the potential short 
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and long-term benefits that these protocols may offer in terms of renal impairment[69,70,72], 
de novo tumours[73], recurrence of hepatocellular carcinoma[74] and graft loss[18], among 
others. In RCTs evaluating more conventional regimens based on CNI, a protocolized 
pathological surveillance may not be strictly warranted, but the criteria to select patients for 
liver biopsy should be standardized to ensure a homogeneous evaluation of ACR. A method 
to identify patients at increased risk of ACR (ie. candidates for liver biopsy) early after LT 
has been seldom attempted, and never fully accomplished. In 1992, a definition of clinical 
suspicion of rejection based on liver tests (ALT increase >50 U/L and/or bilirubin >6 mg/dL 
reversed by antirejection therapy) was compared to histological findings[75]. The correlation 
was not good and 40% of patients biopsied had histological rejection, not encompassed by 
the clinical definition. The HCV3 trial[76] considered a patient at clinical suspicion of ACR 
whenever 3 consecutive test results revealed serum AST or ALT levels elevated 1.5 times 
above the baseline or serum bilirubin elevated by 0.3 mg/dL. In another study patients were 
biopsied provided they had fever, malaise, back or abdominal pain, tenderness or 
enlargement of the liver, a change in bile color, and a rapid increase in transaminases or 
cholestatic parameters[41]. However neither transaminases nor bilirubin (not to say fever, 
malaise or abdominal pain) have shown any diagnostic capacity of ACR in previous 
studies[66,77], and the chosen thresholds for liver tests (if any) were arbitrary, without any 
prior analysis. The actual benefit of these methods is unknown, as the rates of liver biopsy 
due to clinical suspicion of rejection were not reported. However an important concept was 
introduced: a dynamic change on liver tests was considered more appropriate for a non-
invasive suspicion of ACR, rather than static values. The above referred study based on 100 
LT patients with protocol liver biopsies early after LT, explored a multivariate model to 
predict moderate-severe histological ACR based on the product Age by pre-LT MELD, the 
immunosuppression protocol and the delta blood eosinophil count within the 4 days prior to 
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liver biopsy[29]. The area under ROC curve to predict moderate-severe histological ACR 
was 0.84, and it allowed to stratify patients according to the expected rate of ACR, in order to 
guide clinical decisions. The rates of misdiagnosis following the derived algorithm were as 
low as 10%. These results should be validated and further modifications of the model 
explored before recommending its implementation in routine clinical practice. An 
international consensus is urgently needed to define what is meant by clinical suspicion of 
rejection after LT, and it should be based on objective, reproducible and dynamic parameters, 
able to translate the events taking place in the liver graft. Only then an objective assessment 
of rejection will be possible within double blinded RCTs. 
 
2.3) Composite endpoints including biopsy-proven ACR after clinical suspicion should be 
interpreted cautiously  
The doubtful prognostic impact of biopsy-proven ACR as currently assessed has led to the use 
of composite efficacy outcomes including combinations with chronic rejection, graft loss and 
mortality[22,43,44,53,59-61]. In such endpoints, biopsy-proven ACR is a much more frequent 
event and will be the main (and maybe the only significant) contributor to produce outcomes. 
The caveat derived from using composite endpoints with a predominant component is well 
known, for instance, in cardiovascular trials[78], and will not allow to overcome the problem 
of biopsy-proven ACR. The use of chronic rejection, graft loss and mortality as the only 
primary efficacy endpoints would require an unbearable high number of patients with 
prolonged surveillances, thereby increasing costs exponentially and reducing feasibility. 
Nonetheless an observational follow-up of patients included in RCTs evaluating 
immunosuppressants should be systematically extended at least for 5 years to report graft loss 
and mortality rates, as these data may reinforce the justification of the evaluated strategy[23]. 
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A meta-analysis of individual patient data and a network meta-analysis from several RCTs 
using this information would be extremely valuable, particularly for those studies with 
interventional arms prematurely stopped due to increased early ACR rates. It is possible that 
these interventional arms, usually aiming at aggressive minimization or avoidance of 
CNI[47,53], show similar or even improved graft loss and mortality rates than more 
conventional immunosuppression protocols, as already reported in a long-term follow-up of a 
tacrolimus monotherapy RCT[23]. In that case, such aggressive minimization protocols 
should not be discarded, but further investigated for a possible benefit on adverse events. 
Regulatory authorities should consider imposing 5-year reports on chronic rejection, graft 
loss and mortality in RCTs as it would help to determine the optimal immunosuppression 
protocol for each patient, to develop more accurate clinical guidelines, and to allow for a true 
tailored immunosuppression in LT. 
 
3) FUTURE DIRECTIONS 
The long standing promise of personalized medicine is becoming a reality. In solid organ 
transplantation there is an increasing amount of immunosuppressive drugs and combinations. 
Ideally a minority of LT patients at increased risk of aggressive ACR and graft loss may 
require intensive immunosuppression and pathological surveillance of the liver graft, whereas 
immune-tolerant patients would benefit from minimization strategies with an improved safety 
profile, and long-term weaning of immunosuppression[68]. For this purpose the clinician 
needs to be provided with discriminative and not-invasive diagnostic tools. However the 
search of reliable biomarkers for immune-mediated diseases is a real challenge, given the 
intricated mechanisms underlying the activation of the different immune pathways, which in 
turn use to be interconnected and protected by hidden feedback signals.  
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Immune function assays evaluate the response of different components of the immune system 
after a certain stimuli, which can be donor-antigen specific or not-antigen specific[79]. 
Antigen-specific assays confront stimulator cells from the donor with mononuclear cells from 
the recipient, to analyze the amount of cytokines produced. Although the methodology is 
based in a solid rationale, the need of viable donor cells (not available within deceased 
donation), and the lack of standardized procedures, have limited its applicability. Among not 
antigen-specific immune assays the most invoked, and the only approved by Food and Drug 
Administration for immune monitoring, is the Immuknow test (Cylex LTD, United States), 
which measures the production of intracellular adenosine triphosfate by T-CD4+ cells after 
stimulation with phytohemagglutinin. Serial determinations after LT may predict ACR as 
well as consequences of over-immunosuppression such as infections. Unfortunately the 
obtained results are inconsistent. A meta-analysis of five observational studies implementing 
Immuknow after LT (n=543) found a significant heterogeneity among publications. This is 
not surprising since none of these studies were based on protocol liver biopsies, but instead 
used biopsy-proven ACR after clinical suspicion as the gold standard[80]. A recent RCT 
compared a group with standard practice (dose of tacrolimus adjusted according trough 
concentrations) (n=102) with an interventional arm (n=100) in which tacrolimus dosage was 
modified according to serial Immuknow determinations. The immunosuppression protocol 
was tacrolimus and tapering steroids in all patients, although additional immunosuppressants 
were permitted. The interventional arm had reduced trough concentration of tacrolimus, 
which resulted in less infections (42% vs 54.9%; p<0.05), with similar biopsy-proven ACR 
rates (19% vs 13.7%; p=NS), and improved survival rates at 12 months (95% vs 82%; 
p<0.01)[81]. Although it seems that Immuknow adds some information to liver tests and 
trough concentrations of CNI, more studies are warranted to confirm these observations.   
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Flow cytometry is another powerful technique able to detect and quantify activated T cells in 
peripheral blood. In allo-reactive patients the proliferation of activated T cells is an early 
event, providing a perfect window of opportunity to implement changes in 
immunosuppression. Among lymphocyte subpopulations, Th17, activated CD8+ and CD4+ T 
cells are increased in patients with ACR[82-85], whereas Treg cells promote tolerance[86]. 
Again, these results should be interpreted with caution as the gold standard used was any 
grade of biopsy-proven ACR after clinical suspicion. Other strategies based on micro 
RNAs[87-91], mRNAs[92-94], enzyme-linked immunosorbent spots[95], serum cytokines 
concentrations and polymorphisms[96-99], proteomic signatures[100] and genomic 
fingerprints[101-103] have been tested in LT but they are far from becoming a reality in 
clinical practice.   
 
Historically AMR has received little attention in LT since HLA incompatible donors do not 
impact on long term recipient survival[104]. However a single episode of humoral rejection 
increases the risk of chronic rejection[105]. The screening of donor specific antibodies by 
using the luminex system is gaining adepts among kidney transplant physicians, but the 
actual meaning in the LT setting is still unknown. The liver has a tremendous potential to 
clear preformed donor-specific antibodies and most patients will remain free from humoral 
rejection. It seems that the thresholds for donor-specific antibodies in liver recipients should 
be set higher than in renal or heart transplantation[106], but hitherto they are not established. 
Those patients with persistent class II HLA donor-specific antibodies after LT are at 
increased risk of significant rejection and graft loss[106]. However, although a lower 
concentration of donor-specific antibodies increases the risk of ACR, its impact on graft 
survival needs to be further explored[107,108]. Patients developing high titers of persistent 
donor-specific antibodies after LT would provide valuable additional information for RCTs, 
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as they might explain some cases of graft loss of unknown origin[109], and some histological 
criteria have been established[110]. However a more accurate and individualized 
phenotyping will be needed before the implementation of AMR as an endpoint in RCTs in 
LT[111]. 
 
CONCLUSION 
Biopsy-proven ACR after clinical suspicion is an inappropriate efficacy outcome for RCTs 
evaluating immunosuppressive protocols. This shortcoming is hindering the way towards 
minimal immunosuppression and operational tolerance. The LT community has chosen to 
turn a deaf ear on this matter but the evidence calls for a change. In RCTs using aggressive 
minimization regimens, protocol liver biopsies should be implemented, including a central 
and blinded pathology reading. For RCTs with more conventional CNI-based 
immunosuppression, an objective methodology to select candidates for liver biopsy is 
urgently needed in order to homogenize the assessment of ACR among clinicians and 
transplant teams worldwide. In the early post-LT period, only severe episodes of ACR, and 
maybe moderate episodes unresponsive to steroid boluses, should be considered as 
potentially harmful events. Chronic rejection and derived graft loss might be the primary 
efficacy outcomes to measure, and surrogate biomarkers of such events are warranted. 
 
TABLES 
Table 1. Randomized controlled trials evaluating de novo immunosuppression protocols after 
liver transplantation published in full from 2007 to 2015. Definition of acute cellular rejection 
used and design features. 
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AUTHOR YEAR CENTER
S 
(N) 
PRIMARY 
OUTCOME 
BLINDING N ACR 
DEFINITIO
N 
PURE 
CLINICAL 
REJECTIO
N 
FOLLO
W UP 
(months) 
TREATMENT ARMS ACR 
RATES 
(%) 
Trunecka 
[65] 
2015 72 Renal 
function 
Open label 893 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 6 TAC+MMF 18 
Anti-ILr2+TAC+MMF 12.4 
Anti-ILr2+TAC 
(delayed)+MMF 
18.4 
Klintmalm 
[22] 
2014 39 Composite 
(BPAR, graft 
loss and 
death) 
Open label 260   12 TAC+/-MMF 20.6 
BEL_HD+MMF+/-anti-IL2r 36.9 
BEL_LD+MMF 32.7 
Asrani  
[61] 
2014 31 Composite 
(BPAR, graft 
loss and 
death) 
Open label 224 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 24  
TAC+STDs 
 
30.4 
 
SIR+TAC+STDs 
 
26.4 
Levy 
[62] 
2014 45 HCV 
recurrence 
Open label 356 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+/-others 
 
11.2 
 
CyA+/-others 
 
15.4 
Teperman 
[60] 
2013 10 Composite 
(BPAR, graft 
loss and 
death) 
Open label 293 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC/CyA+MMF 
 
10.3 
 
SIR+MMF 
 
11.5 
Takada 
[59] 
2013 6 Composite 
(BPAR, 
recurrence 
hepatitis C, 
graft loss, 
death) 
Open label 75 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+STD 
 
11.4 
 
TAC+MMF 
 
32.5 
Ramirez 
[58] 
2013 1 BPAR Open label 40 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
Anti-
IL2r+TAC+MMF+STD 
 
5 
 
Anti-IL2r+TAC+MMF 
 
5 
Pelletier 
[57] 
2013 1 BPAR Open label 100 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+MMF+STD 
 
14 
 
TAC+MMF 
 
20 
Fischer 
[56] 
2012 15 Renal 
function 
Open label 203 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+STD 
 
15.3 
 
EVE+STD (TAC weaning) 
 
17.7 
Ju 
[54] 
2012 1 BPAR Open label 82 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12 Anti-IL2r+TAC+STDs 7.3 
Anti-IL2r+TAC+STDs (24 
hours avoidance) 
 
9.8 
De Simone 
[53] 
2012 79 Composite 
(BPAR, graft 
loss and 
death) 
Open label 1147 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 24 
 
TAC+STD 18.9 
EVE+STD 26.8 
TAC+EVE+STD 12.3 
Neumann 
[55] 
2012 8 HCV viral 
load 
Open label 135 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+/-MMF+STD 
 
30.9 
 
Anti-IL2r+TAC+/-MMF 
 
16.4 
Fischer 
[63] 
2011 11 Pharmacokin
etics 
Open label 129 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Allowed 2 TACbd+STD 27.4 
 
TACqd+STD 
 
26.9 
Boudjema 
[51] 
2011 7 BPAR Open label 195 Biopsy-
proven no 
Not allowed 12  
TAC+STD 
 
46 
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criteria 
defined for 
liver biopsy 
 
TAC+MMF+STD 
 
30 
Masetti 
[49] 
2010 1 Renal 
function 
Open label 78 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
Anti-IL2r+CyA+STD 
 
7.7 
 
Anti-IL2r+EVE+STD 
 
5.7 
Calmus 
[48] 
2010 14 Renal 
function 
Open label 199 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 24  
TAC+MMF+STD 
 
25.1 
 
Anti-
IL2r+TAC+MMF+STD 
 
24.5 
Trunecka 
[50] 
2010 48 BPAR Double 
blinded 
471 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12 
 
 
TACbd+STD 
 
26.9 
 
TACqd+STD 
 
29.5 
Benítez 
[47] 
2010 1 BPAR Open label 37 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Allowed 12  
TAC+STD 
 
31.2 
 
ATG+TAC (weaning) 
 
66.7 
Nashan 
[44] 
2009 15 Composite 
(BPAR and 
graft loss) 
Open label 60 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+MMF+STD 
 
17 
 
Reduced TAC+MMF+STD 
 
17 
Manousou 
[43] 
2009 3 Composite 
(recurrence 
of hepatitis 
C, 
unresponsive 
rejection and 
graft loss) 
Open label 103 Protocol 
biopsies at 
day 7 
Not allowed 60 
 
 
 
 
TAC+AZA+STD 
 
8.2 
 
TAC montherapy 
 
3.7 
Boillot 
[64] 
2009 1 BPAR Open label 93 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 60 TAC+MMF+STD 14.3 
ATG+TAC+MMF 11.4 
Neuberger 
[46] 
2009 8 Renal 
function 
Open label 525 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Allowed 12 TAC+STD 24.3 
TAC+MMF+STD 26.8 
Anti-
IL2r+TAC+MMF+STD 
16.7 
Otero 
[45] 
2009 12 BPAR Open label 157 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 6  
TAC+STD 
 
26.6 
 
Anti-IL2r+TAC+MMF 
 
11.5 
Shenoy 
[42] 
2008 1 BPAR Open label 60 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Allowed 12  
TAC+STD+/-MMF 
 
27 
 
CyA+STD+/-MMF 
 
23 
Lupo 
[41] 
2008 1 BPAR Open label 47 Biopsy 
proven (if 
fever malaise, 
abdominal 
pain or raising 
transaminases
) 
Not allowed 21  
CyA+STD 
 
28.6 
 
Anti-IL2r+CyA 
 
15.3 
Lerut 
[40] 
2008 1 BPAR Double 
blinded 
156 Protocol 
biopsies at 
day 7 
Not allowed 12 TAC+STD 48.7 
TAC monotherapy 50 
Becker 
[39] 
2008 37 BPAR Open label  Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Allowed 3  
TAC+MMF 
 
16.2 
 
Anti-IL2r+TAC 
 
19.7 
Moench 
[36] 
2007 1 Diabetes, 
dyslipidemia, 
hypertension 
Double 
blinded 
110 Biopsy-
proven no 
criteria 
defined for 
Not allowed 12  
TAC+STD 
 
35.2 
 
TAC+Placebo 
 
41.8 
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ACR: acute cellular rejection; anti-IL2r: anti IL-2 receptor; ATG: antithymocyte globulin; BEL_HD: belatacept high dose; BEL_LD: belatacept 
low dose; BPAR: biopsy-proven acute rejection; CyA: cyclosporine; EVE: everolimus; MMF: mycofelonate; SIR: sirolimus; STD: steroids; 
TAC: tacrolimus.  
  
LEGEND OF FIGURE  
Figure 1. Flow diagram illustrating the search strategy used according to PRISMA (Preferred 
Reporting Items for Systematic reviews and Meta-Analyses) statement[112]. 
 
REFERENCES 
[1]  Pleguezuelo M, Germani G,Burroughs A. Liver Transplantation: prevention and 
treatment of rejection. In: McDonald J, Burroughs A, Feagan B, editors. Evidence-
Based Gastroenterology and Hepatology. Wiley-Blackwell, 2010, pp. 685–723. 
[2]  Thorpe KE, Zwarenstein M, Oxman AD, et al. A pragmatic-explanatory continuum 
indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol, 
2009;62:464. 
liver biopsy 
Vivarelli 
[38] 
2007 2 Recurrence 
of hepatitis C 
Open label 39 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12 TAC+STD (early 
withdrawal) 
8.7 
 
TAC+STD (late 
withdrawal) 
25 
Schmedin
g 
[37] 
2007 1 BPAR Open label 99 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+STD 
 
37.2 
 
Anti-IL2r+TAC+STD 
 
52.1 
Klintmalm 
[76] 
2007 9 BPAR Open label 312 Biopsy-
proven (if  
raising 
transaminases 
or bilirubin) 
Not allowed 12 TAC+STD 35.9 
TAC+MMF+STD 36.6 
Anti-IL2r+TAC+MMF 30.6 
Kato 
[35] 
2007 1 Recurrence 
of Hepatitis 
C 
Open label 70 Biopsy-
proven no 
criteria 
defined for 
liver biopsy 
Not allowed 12  
TAC+STD+/-MMF 
 
38.4 
 
Anti-IL2r+TAC+/-MMF 
 
33 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[3]  Bilbao I. Safety and efficacy of steroid-free immunosuppression post-liver 
transplantation: a randomised phase III trial comparing tacrolimus monotherapy after 
daclizumab induction versus tacrolimus+MMF dual therapy. J Hepatol, 2009;50:S58 
(abstract). 
[4]  Grant D. A randomized, single-center trial comparing thymoglobulin (TG) induction 
therapy and delayed initiation of tacrolimus to no induction with immediate initiation 
of tacrolimus in liver transplant (LT) recipients to assess the impact on renal function. 
Am J Transplant, 2012;12:539 (abstract). 
[5]  Adam R, Karam V, Delvart V, et al. Evolution of indications and results of liver 
transplantation in Europe. A report from the European Liver Transplant Registry 
(ELTR). J Hepatol, 2012;57:675. 
[6]  El Ters M, Grande JP, Keddis MT, et al. Kidney allograft survival after acute rejection, 
the value of follow-up biopsies. Am J Transplant, 2013;13:2334. 
[7]  McManigle W, Pavlisko EN,Martinu T. Acute cellular and antibody-mediated allograft 
rejection. Semin Respir Crit Care Med, 2013;34:320. 
[8]  Stehlik J, Edwards LB, Kucheryavaya AY, et al. The Registry of the International 
Society for Heart and Lung Transplantation: twenty-seventh official adult heart 
transplant report--2010. J Heart Lung Transplant, 2010;29:1089. 
[9]  Ruiz R, Tomiyama K, Campsen J, et al. Implications of a positive crossmatch in liver 
transplantation: a 20-year review. Liver Transpl, 2012;18:455. 
[10]  Nilles KM, Krupp J, Lapin B, Sustento-Reodica N, Gallon L,Levitsky J. Incidence and 
impact of rejection following simultaneous liver-kidney transplantation. J Hepatol, 
2015;62:340. 
[11]  Barbier L, Garcia S, Cros J, et al. Assessment of chronic rejection in liver graft 
recipients receiving immunosuppression with low-dose calcineurin inhibitors. J 
Hepatol, 2013;59:1223. 
[12]  Wiesner RH, Demetris AJ, Belle SH, et al. Acute hepatic allograft rejection: incidence, 
risk factors, and impact on outcome. Hepatology, 1998;28:638. 
[13]  Sharma P, Hosmer A, Appelman H, et al. Immunological dysfunction during or after 
antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int, 
2013;7:990. 
[14]  Uemura T, Ikegami T, Sanchez EQ, et al. Late acute rejection after liver transplantation 
impacts patient survival. Clin Transplant, 2008;22:316. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[15]  Thurairajah PH, Carbone M, Bridgestock H, et al. Late acute liver allograft rejection; a 
study of its natural history and graft survival in the current era. Transplantation, 
2013;95:955. 
[16]  Carbone M,Neuberger JM. Autoimmune liver disease, autoimmunity and liver 
transplantation. J Hepatol, 2014;60:210. 
[17]  Lucey MR, Terrault N, Ojo L, et al. Long-term management of the successful adult liver 
transplant: 2012 practice guideline by the American Association for the Study of 
Liver Diseases and the American Society of Transplantation. Liver Transpl, 
2013;19:3. 
[18]  Rodriguez-Peralvarez M, Germani G, Papastergiou V, et al. Early tacrolimus exposure 
after liver transplantation: relationship with moderate/severe acute rejection and long-
term outcome. J Hepatol, 2013;58:262. 
[19]  Neuberger J. Incidence, timing, and risk factors for acute and chronic rejection. Liver 
Transpl Surg, 1999;5:S30. 
[20]  Wiesner RH,Fung JJ. Present state of immunosuppressive therapy in liver transplant 
recipients. Liver Transpl, 2011;17 Suppl 3:S1. 
[21]  Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E,Burroughs AK. 
Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a 
systematic review and meta-analysis. Am J Transplant, 2012;12:2797. 
[22]  Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo 
liver transplant recipients: 1-year experience from a phase II randomized study. Am J 
Transplant, 2014;14:1817. 
[23]  Lerut JP, Pinheiro RS, Lai Q, et al. Is minimal, [almost] steroid-free 
immunosuppression a safe approach in adult liver transplantation? Long-term 
outcome of a prospective, double blind, placebo-controlled, randomized, investigator-
driven study. Ann Surg, 2014;260:886. 
[24]  Banff schema for grading liver allograft rejection: an international consensus document. 
Hepatology, 1997;25:658. 
[25]  Burroughs AK, Patch DW, Stigliano R,Cecilioni L. Protocol biopsies in liver 
transplantation. Liver Transpl, 2003;9:780. 
[26]  Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy--indications, 
adequacy, quality of specimens, and complications--a systematic review. J Hepatol, 
2007;47:284. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[27]  Al Knawy B,Shiffman M. Percutaneous liver biopsy in clinical practice. Liver Int, 
2007;27:1166. 
[28]  Cross TJ, Antoniades CG, Muiesan P, et al. Liver transplantation in patients over 60 and 
65 years: an evaluation of long-term outcomes and survival. Liver Transpl, 
2007;13:1382. 
[29]  Rodriguez-Peralvarez M, Garcia-Caparros C, Tsochatzis E, et al. Lack of agreement for 
defining 'clinical suspicion of rejection' in liver transplantation: a model to select 
candidates for liver biopsy. Transpl Int, 2015. 
[30]  Wang YC, Wu TJ, Wu TH, et al. The risk factors to predict acute rejection in liver 
transplantation. Transplant Proc, 2012;44:526. 
[31]  Au KP, Chan SC, Chok KS, et al. Clinical factors affecting rejection rates in liver 
transplantation. Hepatobiliary Pancreat Dis Int, 2015;14:367. 
[32]  Bitetto D, Fabris C, Falleti E, et al. Vitamin D and the risk of acute allograft rejection 
following human liver transplantation. Liver Int, 2010;30:417. 
[33]  Falleti E, Bitetto D, Fabris C, et al. Association between vitamin D receptor genetic 
polymorphisms and acute cellular rejection in liver-transplanted patients. Transpl Int, 
2012;25:314. 
[34]  Mittal C, Qureshi W, Singla S, Ahmad U,Huang MA. Pre-transplant left ventricular 
diastolic dysfunction is associated with post transplant acute graft rejection and graft 
failure. Dig Dis Sci, 2014;59:674. 
[35]  Kato T, Gaynor JJ, Yoshida H, et al. Randomized trial of steroid-free induction versus 
corticosteroid maintenance among orthotopic liver transplant recipients with hepatitis 
C virus: impact on hepatic fibrosis progression at one year. Transplantation, 
2007;84:829. 
[36]  Moench C, Barreiros AP, Schuchmann M, et al. Tacrolimus monotherapy without 
steroids after liver transplantation--a prospective randomized double-blinded placebo-
controlled trial. Am J Transplant, 2007;7:1616. 
[37]  Schmeding M, Sauer IM, Kiessling A, et al. Influence of basiliximab induction therapy 
on long term outcome after liver transplantation, a prospectively randomised trial. 
Ann Transplant, 2007;12:15. 
[38]  Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after 
liver transplantation: A prospective study. J Hepatol, 2007;47:793. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[39]  Becker T, Foltys D, Bilbao I, et al. Patient outcomes in two steroid-free regimens using 
tacrolimus monotherapy after daclizumab induction and tacrolimus with 
mycophenolate mofetil in liver transplantation. Transplantation, 2008;86:1689. 
[40]  Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver 
transplantation: one-year results of a prospective, randomized, double-blind, placebo-
controlled study. Ann Surg, 2008;248:956. 
[41]  Lupo L, Panzera P, Tandoi F, et al. Basiliximab versus steroids in double therapy 
immunosuppression in liver transplantation: a prospective randomized clinical trial. 
Transplantation, 2008;86:925. 
[42]  Shenoy S, Hardinger KL, Crippin J, et al. A randomized, prospective, 
pharmacoeconomic trial of neoral 2-hour postdose concentration monitoring versus 
tacrolimus trough concentration monitoring in de novo liver transplant recipients. 
Liver Transpl, 2008;14:173. 
[43]  Manousou P, Samonakis D, Cholongitas E, et al. Outcome of recurrent hepatitis C virus 
after liver transplantation in a randomized trial of tacrolimus monotherapy versus 
triple therapy. Liver Transpl, 2009;15:1783. 
[44]  Nashan B, Saliba F, Durand F, et al. Pharmacokinetics, efficacy, and safety of 
mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus 
in liver transplant recipients. Liver Transpl, 2009;15:136. 
[45]  Otero A, Varo E, de Urbina JO, et al. A prospective randomized open study in liver 
transplant recipients: daclizumab, mycophenolate mofetil, and tacrolimus versus 
tacrolimus and steroids. Liver Transpl, 2009;15:1542. 
[46]  Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose 
tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J 
Transplant, 2009;9:327. 
[47]  Benitez CE, Puig-Pey I, Lopez M, et al. ATG-Fresenius treatment and low-dose 
tacrolimus: results of a randomized controlled trial in liver transplantation. Am J 
Transplant, 2010;10:2296. 
[48]  Calmus Y, Kamar N, Gugenheim J, et al. Assessing renal function with daclizumab 
induction and delayed tacrolimus introduction in liver transplant recipients. 
Transplantation, 2010;89:1504. 
[49]  Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors 
and everolimus monotherapy in de novo liver transplant recipients preserves renal 
function. Am J Transplant, 2010;10:2252. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[50]  Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus 
(ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. 
Am J Transplant, 2010;10:2313. 
[51]  Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate 
mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am 
J Transplant, 2011;11:965. 
[52]  Klintmalm GB, Davis GL, Teperman L, et al. A randomized, multicenter study 
comparing steroid-free immunosuppression and standard immunosuppression for liver 
transplant recipients with chronic hepatitis C. Liver Transpl, 2011;17:1394. 
[53]  De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus 
improves renal function in de novo liver transplant recipients: a randomized 
controlled trial. Am J Transplant, 2012;12:3008. 
[54]  Ju WQ, Guo ZY, Ling X, et al. Twenty-four hour steroid avoidance immunosuppressive 
regimen in liver transplant recipients. Exp Clin Transplant, 2012;10:258. 
[55]  Neumann U, Samuel D, Trunecka P, Gugenheim J, Gerunda GE,Friman S. A 
Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and 
without Steroids in HCV-Positive Liver Allograft Recipients. J Transplant, 
2012;2012:894215. 
[56]  Fischer L, Klempnauer J, Beckebaum S, et al. A Randomized, Controlled Study to 
Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver 
Transplantation-PROTECT. Am J Transplant, 2012;12:1855. 
[57]  Pelletier SJ, Nadig SN, Lee DD, et al. A prospective, randomized trial of complete 
avoidance of steroids in liver transplantation with follow-up of over 7 years. HPB 
(Oxford), 2013;15:286. 
[58]  Ramirez CB, Doria C, Frank AM, Armenti ST,Marino IR. Completely steroid-free 
immunosuppression in liver transplantation: a randomized study. Clin Transplant, 
2013;27:463. 
[59]  Takada Y, Kaido T, Asonuma K, et al. Randomized, multicenter trial comparing 
tacrolimus plus mycophenolate mofetil to tacrolimus plus steroids in hepatitis C virus-
positive recipients of living donor liver transplantation. Liver Transpl, 2013;19:896. 
[60]  Teperman L, Moonka D, Sebastian A, et al. Calcineurin inhibitor-free mycophenolate 
mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-
nephron trial. Liver Transpl, 2013;19:675. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[61]  Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose 
tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 
phase II prospective randomized trial. Am J Transplant, 2014;14:356. 
[62]  Levy G, Villamil FG, Nevens F, et al. REFINE: a randomized trial comparing 
cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C. 
Am J Transplant, 2014;14:635. 
[63]  Fischer L, Trunecka P, Gridelli B, et al. Pharmacokinetics for once-daily versus twice-
daily tacrolimus formulations in de novo liver transplantation: a randomized, open-
label trial. Liver Transpl, 2011;17:167. 
[64]  Boillot O, Seket B, Dumortier J, et al. Thymoglobulin induction in liver transplant 
recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive 
regimen: a five-year randomized prospective study. Liver Transpl, 2009;15:1426. 
[65]  TruneCka P, Klempnauer J, Bechstein WO, et al. Renal Function in De Novo Liver 
Transplant Recipients Receiving Different Prolonged-Release Tacrolimus Regimens-
The DIAMOND Study. Am J Transplant, 2015;15:1843. 
[66]  Rodriguez-Peralvarez M, Germani G, Tsochatzis E, et al. Predicting severity and 
clinical course of acute rejection after liver transplantation using blood eosinophil 
count. Transpl Int, 2012;25:555. 
[67]  Tippner C, Nashan B, Hoshino K, et al. Clinical and subclinical acute rejection early 
after liver transplantation: contributing factors and relevance for the long-term course. 
Transplantation, 2001;72:1122. 
[68]  Adams DH, Sanchez-Fueyo A,Samuel D. From immunosuppression to tolerance. J 
Hepatol, 2015;62:S170. 
[69]  Saliba F, De Simone P, Nevens F, et al. Renal function at two years in liver transplant 
patients receiving everolimus: results of a randomized, multicenter study. Am J 
Transplant, 2013;13:1734. 
[70]  Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor 
withdrawal: 3-year results from a randomized trial in liver transplantation. Am J 
Transplant, 2014;14:701. 
[71]  Hellemans R, Hazzan M, Durand D, et al. Daclizumab Versus Rabbit Antithymocyte 
Globulin in High-Risk Renal Transplants: Five-Year Follow-up of a Randomized 
Study. Am J Transplant, 2015;15:1923. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[72]  Schnitzbauer AA, Sothmann J, Baier L, et al. Calcineurin Inhibitor Free De Novo 
Immunosuppression in Liver Transplant Recipients With Pretransplant Renal 
Impairment: Results of a Pilot Study (PATRON07). Transplantation, 2015. 
[73]  Carenco C, Assenat E, Faure S, et al. Tacrolimus and the risk of solid cancers after liver 
transplant: a dose effect relationship. Am J Transplant, 2015;15:678. 
[74]  Rodriguez-Peralvarez M, Tsochatzis E, Naveas MC, et al. Reduced exposure to 
calcineurin inhibitors early after liver transplantation prevents recurrence of 
hepatocellular carcinoma. J Hepatol, 2013;59:1193. 
[75]  Schlitt HJ, Nashan B, Krick P, et al. Intragraft immune events after human liver 
transplantation. Correlation with clinical signs of acute rejection and influence of 
immunosuppression. Transplantation, 1992;54:273. 
[76]  Klintmalm GB, Washburn WK, Rudich SM, et al. Corticosteroid-free 
immunosuppression with daclizumab in HCV(+) liver transplant recipients: 1-year 
interim results of the HCV-3 study. Liver Transpl, 2007;13:1521. 
[77]  Dickson RC, Lauwers GY, Rosen CB, Cantwell R, Nelson DR,Lau JY. The utility of 
noninvasive serologic markers in the management of early allograft rejection in liver 
transplantation recipients. Transplantation, 1999;68:247. 
[78]  Ferreira-Gonzalez I, Busse JW, Heels-Ansdell D, et al. Problems with use of composite 
end points in cardiovascular trials: systematic review of randomised controlled trials. 
BMJ, 2007;334:786. 
[79]  Sood S,Testro AG. Immune monitoring post liver transplant. World J Transplant, 
2014;4:30. 
[80]  Rodrigo E, Lopez-Hoyos M, Corral M, et al. ImmuKnow as a diagnostic tool for 
predicting infection and acute rejection in adult liver transplant recipients: a 
systematic review and meta-analysis. Liver Transpl, 2012;18:1245. 
[81]  Ravaioli M, Neri F, Lazzarotto T, et al. Immunosuppression Modifications Based on an 
Immune Response Assay: Results of a Randomized, Controlled Trial. 
Transplantation, 2015. 
[82]  Millan O, Rafael-Valdivia L, Torrademe E, et al. Intracellular IFN-gamma and IL-2 
expression monitoring as surrogate markers of the risk of acute rejection and personal 
drug response in de novo liver transplant recipients. Cytokine, 2013;61:556. 
[83]  Millan O, Rafael-Valdivia L, San Segundo D, et al. Should IFN-gamma, IL-17 and IL-2 
be considered predictive biomarkers of acute rejection in liver and kidney transplant? 
Results of a multicentric study. Clin Immunol, 2014;154:141. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[84]  Gerlach UA, Vogt K, Schlickeiser S, et al. Elevation of CD4+ differentiated memory T 
cells is associated with acute cellular and antibody-mediated rejection after liver 
transplantation. Transplantation, 2013;95:1512. 
[85]  Fan H, Li LX, Han DD, Kou JT, Li P,He Q. Increase of peripheral Th17 lymphocytes 
during acute cellular rejection in liver transplant recipients. Hepatobiliary Pancreat 
Dis Int, 2012;11:606. 
[86]  Wang Y, Zhang M, Liu ZW, et al. The ratio of circulating regulatory T cells 
(Tregs)/Th17 cells is associated with acute allograft rejection in liver transplantation. 
PLoS One, 2014;9:e112135. 
[87]  Wei L, Gong X, Martinez OM,Krams SM. Differential expression and functions of 
microRNAs in liver transplantation and potential use as non-invasive biomarkers. 
Transpl Immunol, 2013;29:123. 
[88]  Asaoka T, Hernandez D, Tryphonopoulos P, et al. Clinical significance of intragraft 
miR-122 and -155 expression after liver transplantation. Hepatol Res, 2015;45:898. 
[89]  Farid WR, Pan Q, van der Meer AJ, et al. Hepatocyte-derived microRNAs as serum 
biomarkers of hepatic injury and rejection after liver transplantation. Liver Transpl, 
2012;18:290. 
[90]  Joshi D, Salehi S, Brereton H, et al. Distinct microRNA profiles are associated with the 
severity of hepatitis C virus recurrence and acute cellular rejection after liver 
transplantation. Liver Transpl, 2013;19:383. 
[91]  Hu J, Wang Z, Tan CJ, et al. Plasma microRNA, a potential biomarker for acute 
rejection after liver transplantation. Transplantation, 2013;95:991. 
[92]  Kobayashi S, Nagano H, Marubashi S, et al. Guanylate-binding protein 2 mRNA in 
peripheral blood leukocytes of liver transplant recipients as a marker for acute cellular 
rejection. Transpl Int, 2010;23:390. 
[93]  Minisini R, Giarda P, Grossi G, et al. Early activation of interferon-stimulated genes in 
human liver allografts: relationship with acute rejection and histological outcome. J 
Gastroenterol, 2011;46:1307. 
[94]  Asaoka T, Marubashi S, Kobayashi S, et al. Intragraft transcriptome level of CXCL9 as 
biomarker of acute cellular rejection after liver transplantation. J Surg Res, 
2012;178:1003. 
[95]  Truong DQ, Bourdeaux C, Wieers G, Saussoy P, Latinne D,Reding R. The 
immunological monitoring of kidney and liver transplants in adult and pediatric 
recipients. Transpl Immunol, 2009;22:18. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[96]  Wu W, Liu Y, Li S, et al. Association between IL-4 polymorphism and acute rejection 
of solid organ allograft: a meta-analysis. Gene, 2013;513:14. 
[97]  Akoglu B, Kriener S, Martens S, et al. Interleukin-2 in CD8+ T cells correlates with 
Banff score during organ rejection in liver transplant recipients. Clin Exp Med, 
2009;9:259. 
[98]  Kamei H, Masuda S, Nakamura T, et al. Cytokine gene polymorphisms in acute cellular 
rejection following living donor liver transplantation: analysis of 155 donor-recipient 
pairs. Hepatol Int, 2013;7:916. 
[99]  Raschzok N, Reutzel-Selke A, Schmuck RB, et al. CD44 and CXCL9 serum protein 
levels predict the risk of clinically significant allograft rejection after liver 
transplantation. Liver Transpl, 2015;21:1195. 
[100]  Massoud O, Heimbach J, Viker K, et al. Noninvasive diagnosis of acute cellular 
rejection in liver transplant recipients: a proteomic signature validated by enzyme-
linked immunosorbent assay. Liver Transpl, 2011;17:723. 
[101]  Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to 
develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin 
Invest, 2008;118:2845. 
[102]  Legaz I, Lopez-Alvarez MR, Campillo JA, et al. KIR gene mismatching and KIR/C 
ligands in liver transplantation: consequences for short-term liver allograft injury. 
Transplantation, 2013;95:1037. 
[103]  Korkmaz KS, Ten Hove WR, de Rooij BJ, et al. Acute cellular rejection is associated 
with matrix metalloproteinase-2 genotype chimerism after orthotopic liver 
transplantation. Transplant Proc, 2013;45:558. 
[104]  Andres GA, Ansell ID, Halgrimson CG, et al. Immunopathological studies of 
orthotopic human liver allografts. Lancet, 1972;1:275. 
[105]  Demetris AJ, Zeevi A,O'Leary JG. ABO-compatible liver allograft antibody-mediated 
rejection: an update. Curr Opin Organ Transplant, 2015;20:314. 
[106]  O'Leary JG, Demetris AJ, Friedman LS, et al. The role of donor-specific HLA 
alloantibodies in liver transplantation. Am J Transplant, 2014;14:779. 
[107]  Musat AI, Agni RM, Wai PY, et al. The significance of donor-specific HLA antibodies 
in rejection and ductopenia development in ABO compatible liver transplantation. 
Am J Transplant, 2011;11:500. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
[108]  Musat AI, Pigott CM, Ellis TM, et al. Pretransplant donor-specific anti-HLA 
antibodies as predictors of early allograft rejection in ABO-compatible liver 
transplantation. Liver Transpl, 2013;19:1132. 
[109]  O'Leary JG, Kaneku H, Demetris AJ, et al. Antibody-mediated rejection as a 
contributor to previously unexplained early liver allograft loss. Liver Transpl, 
2014;20:218. 
[110]  Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of c4d-
negative antibody-mediated rejection and antibody-associated arterial lesions. Am J 
Transplant, 2014;14:272. 
[111]  O'Leary JG, Michelle Shiller S, Bellamy C, et al. Acute liver allograft antibody-
mediated rejection: an inter-institutional study of significant histopathological 
features. Liver Transpl, 2014;20:1244. 
[112]  Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting 
systematic reviews and meta-analyses of studies that evaluate healthcare 
interventions: explanation and elaboration. BMJ, 2009;339:b2700. 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
